Wednesday 3 July 2024

The Pharma Letter Podcast — Episode 2 — Non-opioid analgesics

Biotechnology
Simon Wentworth
22 July 2021
podcast-episode2

More on this story...

Pharmaceutical
Virtual launch for non-opioid analgesic Anjeso
23 April 2020
Pharmaceutical
US FDA approves non-opioid analgesic from Baudax Bio
21 February 2020
Pharmaceutical
Analgesics market to hit expected to hit $79 billion by 2028
16 August 2018
Biotechnology
The Pharma Letter Podcast — Episode 4 — The state of biotech investing
1 September 2021


Related company news

Mesoblast plots next steps to gain approval of twice rejected Ryoncil
Mesoblast tanks as FDA issues CRL
BRIEF—Mesoblast appoints new chief medical officer
Mesoblast presents latest low back pain data
More ones to watch >


Today's issue

Pharmaceutical
Access to medicines key to British voters, survey shows
3 July 2024
Generics
US authorities clear Mylan in long-running antitrust probe
3 July 2024
Biotechnology
Touchlight and LeninBio announce link up
3 July 2024
Pharmaceutical
Pentixapharm pads pipeline with strategic acquisition
3 July 2024
Biotechnology
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Biotechnology
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
Biotechnology
First COPD nod could add billions to Dupixent revenue
3 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Biotechnology

Touchlight and LeninBio announce link up
3 July 2024
Beacon Therapeutics raises $170 million in a Series B financing
3 July 2024
Lilly's Alzheimer’s drug Kisunla wins FDA approval
3 July 2024
First COPD nod could add billions to Dupixent revenue
3 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze